Clinical Trials Browser

Withdrawn × Cholangiocarcinoma × Breast × Clear all

NCT04985357 2024-11-25

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

BreastEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Anus Neoplasms, Appendiceal Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Laryngeal Neoplasms, Lip Neoplasms, Lung Neoplasms, Mesothelioma, Mouth Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Paranasal Sinus Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Thymoma, Vulvar Neoplasms, Pleural Effusion, Malignant, Carcinoma, Neuroendocrine, Cholangiocarcinoma, Carcinoma, Ductal, Small Cell Lung Carcinoma

NCT03563352 2020-12-14

Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer

Withdrawn

BreastGastrointestinalGenitourinary

Breast Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT01501604 2015-09-17

BKM120 in Cancers With PIK3CA Activating Mutations

Phase 2 Withdrawn

BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma